Implementing Effective Early Phase Trial Strategies in Asia to Reduce Approval Timelines, Risks and Costs from First-In-Human through Proof of Concept

Asia’s ONLY Early Phase Clinical Trials Event!

In March 2012, the number of clinical trials registered in Asia reached almost 19,922. Also, we have seen a significant increase in the number of early-phase clinical trials conducted in Asia with more and more multinational pharmaceutical and biopharmaceutical companies planning early phase clinical trials including First-in-Human trials in the next 2 years.

Expert Speaker Faculty

  • danny-soonDanny Soon
    Managing Director & Principal Investigator
    Lilly-NUS Centre for Clinical Pharmacology, Singapore

    Zaiqi-WangZaiqi Wang
    Director of Clinical Research
    Singapore MSD Translational Research Centre

    Devan-Parmar1Deven Parmar
    Vice President - Global Clinical Research
    Wockhardt
  • Hanlim-MoonHanlim Moon
    Oncology Medical Director, China and Asia
    GlaxoSmithKline

    Rupesh-PatkiRupesh Patki
    Regional Area Manager, Asia Global Monitoring Operations
    Allergan Singapore

    nospeaker1Joalin Lim
    Director, Clinical Affairs
    Covidien
  • Melvin-TohMelvin Toh
    Vice President of Clinical &
    Regulatory Affairs
    CK Life Sciences International

    Joanne ChioJoanne Chio
    Head of Clinical Trials, Haematology –Oncology Research Group (HORG)
    National University Hospital, Singapore

    Ling-SuLing Su
    Senior Vice President & Head of Development Greater China
    Novartis
  • nospeaker1Anthony Johnson
    Vice President, Discovery Medicine Clinical Pharmacology
    Bristol-Myers Squibb

    nospeaker1Akhilesh Sharma
    VP & Global Head of Clinical Management & Global Pharmacovigilance
    Dr Reddy's Laboratories

    nospeaker1Christine Dela Cruz
    Director, Global Clinical Research – Oncology
    Bristol-Myers Squibb
  • nospeaker1Aung Myo
    Head of Clinical Development, Cancer Immunotherapeutics, Asia-Pacific(APJEM)
    GlaxoSmithKline Biologicals

What strategies are you putting in place to reduce timelines and prevent early and late phase failures?

The 2nd Annual Early Phase Clinical Trials Asia 2012 summit is returning this August as a high-level platform to gather Heads of Clinical Development/Research, Medical Directors, Principle Investigators, Heads of R & D from pharmaceutical, biopharmaceutical companies and CROs from Mainland China, India, Taiwan, Korea, Hong Kong and other Southeast Asian countries. They will discuss the most efficient way to overcome regulatory, scientific and operational challenges in developing early phase clinical trials in Asian markets.

Early Phase Clinical Trials Asia 2012 will focus on 3 key areas:

  • Asian regulatory updates on conducting early stage clinical trials and how you can reduce your registration timelines
  • Operational case-studies on how you can effectively conduct early stage clinical trials in a cost-effective manner
  • Proven early phase trial design strategies so that you can reduce later stage trial failure rates

» View the agenda now

» Register now

Attend Early Phase Clinical Trials Asia 2012 and:

  • Learn effective approaches to overcome regulatory challenges for early phase trial approval in China, India and Korea
  • Improve your translational strategy: Align preclinical models with optimised clinical strategies
  • Design a streamlined safety early phase study to mitigate risks and costs
  • Outsource strategies and partnership selection and maintenance with CROs
  • Utilise effective modelling and simulation tools – Examine how this has been successfully used

» Register now

PLUS! Don’t miss our expert-led workshops:

  • Workshop A: Understanding Regulatory Requirements for Conducting Early Development Trials in China to Reduce Registration Timelines
  • Workshop B: Guideline on Strategies to Identify and Mitigate Risks for First-In-Human Clinical Trials in order to Ensure Safety, Efficiency for Selected Patient Populations
Media Partners
_mediapartners

[ Register Now ]